Inhalable Drugs Market to Witness Huge Growth by 2025: Analysis by Trends, Share and Top Key Players - Pfizer, NanoDerma, Aradigm, Alkerme, Dura Pharmaceuticals

Global Inhalable Drugs Market Synopsis:

The report covers a forecast and an analysis of the Inhalable Drugs Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Inhalable Drugs Market along with the impact they have on the demand over the forecast period.

One of the most important key factor drives the growth of the Global Inhalable Drugs Market is rapid growth in the prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis. As per the World Health Organization (WHO), globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273387 .

Based on the regional analysis, North America dominated the overall market in terms of revenue in 2018, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. APAC Inhalable Drugs Market is anticipated to be the fastest-growing segment over the forecast period. Growing medical tourism in several Asian countries is also attracting the attention of leading global players to set up in numerous emerging economies with significant growth potential.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Inhalable Drugs Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 NanoDerma

2 Pfizer

3 Aradigm Corporation

4 Alkerme

5 Dura Pharmaceuticals

6 AeroGen and Inhale Therapeutic Systems and More…………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Inhalable Drugs Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273387/single .

Product Type Segmentation

1 Suspension Aerosol

2 Solution Aerosol

3 Dry Powder Formulation

Industry Segmentation

1 Respiratory diseases

2 Non-respiratory diseases

Latest Medical Industry News:

Pfizer (July 09, 2020) - Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance - Pfizer Inc. announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development.

“As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis,” said Pfizer Chairman and Chief Executive Albert Bourla. “We strongly believe the world cannot tackle the growing threat of AMR without collaboration – and that it will take a combination of prevention measures, responsible stewardship and innovative thinking to overcome existing obstacles. The new AMR Action Fund gives us the vehicle to do that by investing in and stimulating a potentially stronger pipeline for antimicrobial medicines.”

Each year 700,000 people die from AMR. By 2050, it is estimated that AMR could claim as many as 10 million lives per year. To combat AMR, antibiotics should only be used when necessary to preserve their effectiveness.

While antibiotics revolutionized medicine in the 20th century and, together with vaccination, have led to the near eradication of many diseases in the developed world, over time, bacteria change and adapt to the use of antibiotics, rendering them ineffective. This makes it more difficult to treat common infections such as pneumonia, tuberculosis and salmonellosis, leading to longer hospital stays, higher medical costs and increased mortality.

Pfizer takes a multi-pronged approach to tackling AMR. We are a leading developer of vaccines that help prevent infections in the first place, reducing the need for antibiotics that may result in resistant strains. We are also one of the few large research-based pharmaceutical companies still active in research and development for anti-infectives, and work with partners to close critical prevention and treatment gaps in infectious disease around the globe. In addition, we are committed to responsible antibiotic stewardship, and are proud to offer one of the largest and most accessible AMR surveillance programs in the world, called ATLAS – the only platform that provides public access to both antifungal and antibacterial resistance data through a single resource. ATLAS is accessible freely to anyone, anywhere via the Web or the ATLAS mobile application.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273387 .

Major Points in Table of Contents:

Global Inhalable Drugs Market Report 2020

1 Inhalable Drugs Product Definition

2 Global Inhalable Drugs Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Inhalable Drugs Shipments

2.2 Global Manufacturer Inhalable Drugs Business Revenue

2.3 Global Inhalable Drugs Market Overview

2.4 COVID-19 Impact on Inhalable Drugs Industry

3 Manufacturer Inhalable Drugs Business Introduction

3.1 NanoDerma Inhalable Drugs Business Introduction

3.2 Pfizer Inhalable Drugs Business Introduction

3.3 Aradigm Corporation Inhalable Drugs Business Introduction

3.4 Alkerme Inhalable Drugs Business Introduction

3.5 Dura Pharmaceuticals Inhalable Drugs Business Introduction

3.6 AeroGen and Inhale Therapeutic Systems Inhalable Drugs Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.